Primary Gastric Lymphomas

AA Danilenko, SV Shakhtarina, NA Falaleeva

AF Tsyb Medical Research Center for Radiology, Division of National Medical Radiology Research Center, 4 Koroleva str., Kaluga Region, Obninsk, Russian Federation, 249036

For correspondence: Anatolii Aleksandrovich Danilenko, MD, PhD, 4 Koroleva str., Kaluga Region, Obninsk, Russian Federation, 249036; Tel.: +7(909)250-18-10; e-mail:

For citation: Danilenko AA, Shakhtarina SV, Falaleeva NA. Primary Gastric Lymphomas. Clinical oncohematology. 2020;13(1):95–103 (In Russ).

DOI: 10.21320/2500-2139-2020-13-1-95-103


Primary gastric lymphomas (PGL) are more common than lymphomas with involvement of other organs and cover a wide spectrum of immunomorphological variants: from indolent marginal zone lymphoma to aggressive diffuse large B-cell lymphoma. PGLs are not characterized with any specific clinical manifestations, which sometimes leads to misdiagnosis. Due to the rareness of the disease many PLG-related issues remain unresolved, this provided the background for the present review.

Keywords: primary gastric lymphomas, diffuse large B-cell lymphoma, MALT lymphoma, Helicobacter pylori.

Received: July 29, 2019

Accepted: December 5, 2019

Read in PDF


  1. Groves F, Linet M, Travis L, Devesa S. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92(15):1240–51. doi: 10.1093/jnci/92.15.1240.

  2. Chiu B, Weisenburger D. An update of the epidemiology of non-Hodgkin’s lymphoma. Clin Lymphoma. 2003;4(3):161–8. doi: 10.3816/clm.2003.n.025.

  3. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17(6):697–707. doi: 10.3748/wjg.v17.i6.697.

  4. Al-Akwaa AM, Siddiqui N, Al-Mofleh IA. Primary gastric lymphoma. World J Gastroenterol. 2004;10(1):5–11. doi: 10.3748/wjg.v10.i1.5.

  5. Ohkura Y, Lee S, Kaji D, et al. Spontaneous perforation of primary gastric malignant lymphoma: a case report and review of the literature. World J Surg Oncol. 2015;13(1):35. doi: 10.1186/s12957-015-0458-0.

  6. Ahmed N. 23 years of the discovery of Helicobacter pylori: Is the debate over? Ann Clin Microbiol Antimicrob. 2005;4(1):17. doi: 10.1186/1476-0711-4-17.

  7. Mommersteeg MC, Yu J, Peppelenbosch MP, Fuhler GM. Genetic host factors in Helicobacter pylori-induced carcinogenesis: Emerging new paradigms. Biochim Biophys Acta Rev Cancer. 2018;1869(1):42–52. doi: 10.1016/j.bbcan.2017.11.003.

  8. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338(8776):1175–6. doi: 10.1016/0140-6736(91)92035-z.

  9. Zullo A, Hassan C, Ridola L, et al. Gastric MALT lymphoma: old and new insights. Ann Gastroenterol. 2014;27(1):27–33.

  10. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507–13. doi: 10.1136/gutjnl-2011-300495.

  11. Craig VJ, Cogliatti SB, Arnold I, et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia. 2010;24(6):1186–96. doi: 10.1038/leu.2010.76.

  12. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol. 1996;178(2):122–7. doi: 10.1002/(sici)1096-9896(199602)178:2<122::aid-path486>;2-d.

  13. Hussell T, Isaacson PG, Crabtree JE, et al. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet. 1993;342(8871):571–4. doi: 10.1016/0140-6736(93)91408-e.

  14. Sugizaki K, Tari A, Kitadai Y, et al. Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan. Helicobacter. 2018;23(2):e12474. doi: 10.1111/hel.12474.

  15. Saito M, Masutani M, Mabe K, et al. Regression of gastric de novo diffuse large B-cell lymphoma following Helicobacter pylori eradication: a case report. Acta Gastroenterol Belg. 2016;79(3):367–9.

  16. Verduzco-Rodriguez L, Ramirez-Perez F, Clendenin RM, Cruz Lara LA. H. pylori-associated gastric lymphoma: Complete remission in an HIV-positive patient treated with HAART and H. pylori eradication therapy. Rev Gastroenterol Mex. 2017;82(1):92–4. doi: 10.1016/j.rgmxen.2016.05.001.

  17. Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119(21):4838–44. doi: 10.1182/blood-2012-01-404194.

  18. Cui X, Zhou T, Jiang D, et al. Clinical manifestations and endoscopic presentations of gastric lymphoma: a multicenter seven year retrospective survey. Rev Esp Enferm Dig. 2017;109(8):566–71. doi: 10.17235/reed.2017.4882/2017.

  19. Малихова О.А., Поддубный Б.К., Кувшинов Ю.П., Фролова И.П. Роль новейших технологий в эндоскопической диагностике и оценке эффективности лечения лимфом желудка. Современная онкология. 2005;7(3):111–7.

    [Malikhova OA, Poddubnyi BK, Kuvshinov YuP, Frolova IP. The role of novel technologies in endoscopic diagnosis and efficacy evaluation of gastric lymphoma treatment. Sovremennaya onkologiya. 2005;7(3):111–7. (In Russ)]

  20. Малихова О.А., Поддубный Б.К., Поддубная И.В., Концева А.Ю. Неходжкинские лимфомы желудка, современное состояние проблемы. Экспериментальная и клиническая гастроэнтерология. 2010;9:33–7.

    [Malikhova OA, Poddubnyi BK, Poddubnaya IV, Kontseva AYu. Gastric non-Hodgkin’s lymphomas, state of the art. Eksperimental’naya i klinicheskaya gastroenterologiya. 2010;9:33–7. (In Russ)]

  21. Малихова О.А., Поддубная И.В., Черкес Л.В. и др. Эндоскопическая и эндосонографическая диагностика неходжкинских лимфом желудка. Клиническая онкогематология. 2012;5(4):305–15.

    [Malikhova OA, Poddubnaya IV, Cherkes LV, et al. Endoscopic and endosonographic diagnosis of gastric non-Hodgkin’s lymphomas. Klinicheskaya onkogematologiya. 2012;5(4):305–15. (In Russ)]

  22. Vetro C, Chiarenza A, Romano A, et al. Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management. Clin Lymph Myel Leuk. 2014;14(3):179–85. doi: 10.1016/j.clml.2013.10.010.

  23. Park YH, Kim WS, Bang SM, et al. What is stage II in high-grade primary gastric lymphoma? How to define the range of “localized disease”. Leuk Res. 2007;31(8):1039–43. doi: 10.1016/j.leukres.2006.08.021.

  24. Toyoshima O, Nishizawa T, Sakitani K, et al. Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age: A cross-sectional study. World J Gastroenterol. 2018;24(35):4061–8. doi: 10.3748/wjg.v24.i35.4061.

  25. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357(9249):39–40. doi: 10.1016/S0140-6736(00)03571-6.

  26. Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23(22):5061–6. doi: 10.1200/JCO.2005.05.660.

  27. Rohatiner A, d’Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5(5):397–400. doi: 10.1093/oxfordjournals.annonc.a058869.

  28. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19(18):3861–73. doi: 10.1200/jco.2001.19.18.3861.

  29. Ruskone-Fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas. Gut. 2003;52(6):912–3. doi: 10.1136/gut.52.6.912.

  30. Bartlett DL, Karpeh MS Jr, Filippa DA, Brennan MF. Long-term follow-up after curative surgery for early gastric lymphoma. Ann Surg. 1996;223(1):53–62. doi: 10.1097/00000658-199601000-00008.

  31. Selcukbiricik F, Tural D, Elicin O, et al. Primary Gastric Lymphoma: Conservative treatment modality is not inferior to surgery for early-stage disease. ISRN Oncol. 2012;2012:1–6. doi: 10.5402/2012/951816.

  32. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma – results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19(18):3874–83. doi: 10.1200/jco.2001.19.18.3874.

  33. Binn M, Ruskone-Fourmestraux A, Lepage E, et al. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol. 2003;14(12):1751–7. doi: 10.1093/annonc/mdg495.

  34. Aviles A, Nambo MJ, Neri N, et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg. 2004;240(1):44–50. doi: 10.1097/01.sla.0000129354.31318.f1.

  35. Aviles A, Nambo MJ, Neri N, et al. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol. 2005;22(1):57–62. doi: 10.1385/mo:22:1:057.

  36. Spectre G, Libster D, Grisariu S, et al. Bleeding, obstruction, and perforation in a series of patients with aggressive gastric lymphoma treated with primary chemo-therapy. Ann Surg Oncol. 2006;13(11):1372–8. doi: 10.1245/s10434-006-9069-x.

  37. Неред С.Н., Шаленков В.А., Стилиди И.С., Поддубная И.В. Хирургическое и консервативное лечение осложненных форм неходжкинских лимфом желудка. Онкология. 2012;1:28–32.

    [Nered SN, Shalenkov VA, Stilidi IS, Poddubnaya IV. Surgical and conservative treatment of complicated forms of gastric non-Hodgkin’s lymphomas. Onkologiya. 2012;1:28–32. (In Russ)]

  38. Kayali S, Aloe R, Bonaguri C, et al. Non-invasive tests for the diagnosis of helicobacter pylori: state of the art. Acta Biomed. 2018;89(Suppl 8):58–64. doi: 10.23750/abm.v89i8-S.7910.

  39. Fuccio L, Laterza L, Zagari RM, et al. Treatment of Helicobacter pylori infection. BMJ. 2008;337:a1454. doi: 10.1136/bmj.a1454.

  40. Zullo A, Hassan C, Andriani A, et al. Eradication Therapy for Helicobacter pylori in Patients With Gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol. 2009;104(8):1932–7. doi: 10.1038/ajg.2009.314.

  41. Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23(31):8018–24. doi: 10.1200/JCO.2005.02.3903.

  42. Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol. 2009;20(6):1086–93. doi: 10.1093/annonc/mdn760.

  43. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.e14. doi: 10.1053/j.gastro.2016.04.006.

  44. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut. 2003;52(11):1656. doi: 10.1136/gut.52.11.1656.

  45. Debraekeleer A, Remaut H. Future perspective for potential Helicobacter pylori eradication therapies. Fut Microbiol. 2018;13(6):671–87. doi: 10.2217/fmb-2017-0115.

  46. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–33. doi: 10.1111/apt.13497.

  47. Hu Y, Zhu Y, Lu NH. Primary antibiotic resistance of Helicobacter pylori in China. Digest Dis Sci. 2017;62(5):1146–54. doi: 10.1007/s10620-017-4536-8.

  48. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. doi: 10.1136/gutjnl-2016-312288.

  49. Tseng YY, Liou JM, Hsu TL, et al. Development of bacterial transglycosylase inhibitors as new antibiotics: moenomycin A treatment for drug-resistant Helicobacter pylori. Bioorg Med Chem Lett. 2014;24(11):2412–4. doi: 10.1016/j.bmcl.2014.04.041.

  50. Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci. 2014;1:1–19. doi: 10.3389/fmolb.2014.00019.

  51. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14. doi: 10.1038/nrgastro.2014.66.

  52. McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroenterol J. 2016;4(4):546–61. doi: 10.1177/2050640615617358.

  53. Lorca GL, Wadstrom T, Valdez GF, Ljungh A. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39–44. doi: 10.1007/s002840010175.

  54. Pinchuk IV, Bressollier P, Verneuil B, et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother. 2001;45(11):3156–61. doi: 10.1128/AAC.45.11.3156-3161.2001.

  55. Chenoll E, Casinos B, Bataller E, et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol. 2011;77(4):1335–43. doi: 10.1128/AEM.01820-10.

  56. Asano N, Iijima K, Koike T, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: a review. World J Gastroenterol. 2015;21(26):8014–20. doi: 10.3748/wjg.v21.i26.8014.

  57. Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):144–8. doi: 10.1093/annonc/mdt343.

  58. Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Ann Oncol. 2013;24(5):1352–9. doi: 10.1093/annonc/mds644.

  59. Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013;31(5):565–72. doi: 10.1200/JCO.2011.40.6272.

  60. Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905–12. doi: 10.1200/JCO.2016.70.6994.

  61. Streubel B, Ye H, Du MQ, et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology. 2004;66(6):476–80. doi: 10.1159/000079502.

  62. Поддубная И.В., Пробатова Н.А., Ковригина А.М. и др. Первичные MALT-лимфомы желудка различной степени злокачественности: проблемы диагностики и тактики лечения. Современная онкология. 1999;1(1):10–3.

    [Poddubnaya IV, Probatova NA, Kovrigina AM, et al. Primary gastric MALT lymphomas of various tumor grades: diagnosis challenges and treatment tactics. Sovremennaya onkologiya. 1999;1(1):10–3. (In Russ)]

  63. Поддубная И.В. Неходжкинские лимфомы. В кн.: Клиническая онкогематология. Под ред. М.А Волковой. М.: Медицина, 2001. С. 336–75.

    [Poddubnaya IV. Non-Hodgkin’s lymphomas. In: Volkova MA, ed. Klinicheskaya onkogematologiya. (Clinical oncohematology.) Moscow: Meditsina Publ.; 2001. pp. 336–75. (In Russ)]

  64. Поддубная И.В., Османов Е.А., Москаленко О.А. и др. Клинические аспекты MALT-лимфом. Вестник Московского онкологического общества. 2009;10:5–6.

    [Poddubnaya IV, Osmanov EA, Moskalenko OA, et al. Clinical aspects of MALT lymphomas. Vestnik Moskovskogo onkologicheskogo obshchestva. 2009;10:5–6. (In Russ)]

  65. Wirth A, Gospodarowicz M, Aleman BM, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol. 2013;24(5):1344–51. doi: 10.1093/annonc/mds623.

  66. Ruskone-Fourmestraux A, Matysiak-Budnik T, Fabiani B, et al. Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: results of a prospective study with a long term follow-up. Radiother Oncol. 2015;117(1):178–82. doi: 10.1016/j.radonc.2015.08.029.

  67. Paydas S. Helicobacter pylori eradication in gastric diffuse large B cell lymphoma. World J Gastroenterol. 2015;21(13):3773–6. doi: 10.3748/wjg.v21.i13.3773.

  68. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42. doi: 10.1056/nejmoa011795.

  69. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5. doi: 10.1182/blood-2010-03-276246.

  70. Aviles A, Castaneda C, Cleto S, et al. Rituximab and chemotherapy in primary gastric lymphoma. Cancer Biother Radiopharm. 2009;24(1):25–8. doi: 10.1089/cbr.2008.0507.

  71. Leopardo D, Di Lorenzo G, De Renzo A, et al. Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. World J Gastroenterol. 2010;16(20):2526–30. doi: 10.3748/wjg.v16.i20.2526.

  72. Sohn BS, Kim SM, Yoon DH, et al. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Ann Hematol. 2012;91(11):1731–9. doi: 10.1007/s00277-012-1512-4.

  73. Martinelli G, Gigli F, Calabrese L, et al. Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. Leuk Lymphoma. 2009;50(6):925–31. doi: 10.1080/10428190902912478.

  74. Tanaka T, Shimada K, Yamamoto K, et al. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. Ann Hematol. 2012;91(3):383–90. doi: 10.1007/s00277-011-1306-0.

  75. Виноградова Ю.Н., Ильин Н.В. Лучевая терапия в комбинированном лечении неходжкинских лимфом. Злокачественные опухоли. 2015;4(спецвыпуск 2):44–8. doi: 10.18027/2224-5057-2015-4s2-44-48.

    [Vinogradova JN, Ilyin NV. Radiation therapy in the combined treatment of non-Hodgkin’s lymphomas. Malignant tumors. 2015;4(special issue 2):44–8. doi: 10.18027/2224-5057-2015-4s2-44-48. (In Russ)]

  76. Паньшин Г.А., Измайлов Т.Р. Роль радиотерапии в лечении первичных неходжкинских лимфом желудка. Трудный пациент. 2018;16(11):54–6. doi: 10.24411/2074-1995-2018-10032.

    [Panshin GA, Izmailov TR. The role of radiotherapy in the treatment of primary non-Hodgkin’s stomach lymphomas. Trudnyi patsient. 2018;16(11):54–6. doi: 10.24411/2074-1995-2018-10032. (In Russ)]

  77. Pfreundschuh M, Christofyllakis K, Altmann B, et al. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. J Clin Oncol. 2017;35(15 Suppl):7506. doi: 10.1200/jco.2017.35.15_suppl.7506.

  78. Каприн А.Д., Галкин В.Н., Жаворонков Л.П. и др. Синтез фундаментальных и прикладных исследований — основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017;26(2):26–40.

    [Kaprin AD, Galkin VN, Zhavoronkov LP, et al. Synthesis of fundamental and applied research is the basis for ensuring a high level of scientific results and their implementation into medical practice. Radiatsiya i risk. 2017;26(2):26–40. (In Russ)]

  79. Каприн А.Д., Мардынский Ю.С., Смирнов В.П. и др. К истории развития лучевой терапии (часть I). Biomedical Photonics. 2019;8(1):52–62. doi: 10.24931/2413-9432-2019-8-1-52-62.

    [Kaprin AD, Mardinskiy YS, Smirnov VP, et al. The history of radiation therapy (part I). Biomedical Photonics. 2019;8(1):52–62. doi: 10.24931/2413-9432-2019-8-1-52-62. (In Russ)]